AstraZeneca to buy Amolit Pharma for $1.05bn to boost rare disease portfolio
Drug maker AstraZeneca said on Thursday it will acquire rare endocrine disease company Amolyt Pharma for $1.05 billion in cash in a bid to boost its rare disease portfolio.
POPULAR POSTS
Earthquakes and emissions undermine the idea of carbon storage in Texas
December 17, 2024
Rescuers search for cyclone survivors in devastated Mayotte
December 17, 2024
“Gilmore Girls” airs for a second season on Hulu
December 17, 2024
LIVE STREAM
